The hCG Trigger Shot: Dose, the 36 Hour Window, and When It Stops Faking a Positive Test

The trigger shot is the one injection in a fertility cycle where being two hours late changes the outcome. Everything before it can absorb a small scheduling error. The trigger cannot, because it starts a biological clock that ends with either a retrieval or an ovulation, and the lab is already booked. This guide covers what the trigger actually does, why the timing window is what it is, how the doses compare across products, and the part nobody explains properly: exactly how long the injected hormone keeps showing up on a pregnancy test.

What the trigger replaces

In an unmedicated cycle, a surge of luteinising hormone from the pituitary does three things over roughly 36 hours. It completes the final maturation of the egg, restarting a meiotic division that has been paused since before you were born. It loosens the cumulus cells holding the egg to the follicle wall. And it ruptures the follicle so the egg is released.

Stimulated cycles suppress that surge deliberately, with a GnRH antagonist or agonist, so that follicles can be grown to a chosen size without the body ovulating them early and wasting the cycle. Once the follicles are ready, the suppressed surge has to be replaced from outside.

Human chorionic gonadotropin is used for this because it binds the same receptor as LH. It is a structural near-relative: the alpha subunit of hCG is essentially identical to the alpha subunit of LH, FSH and TSH, and the beta subunit is what differentiates them. Functionally the labels describe hCG action as virtually identical to pituitary LH, with a small amount of FSH activity as well. The important practical difference is duration. hCG has a much longer half life than LH, so a single injection sustains the signal that the body would have delivered as a short burst.

The 36 hour window and why it is not negotiable

Ovulation follows the LH surge by roughly 36 to 40 hours. That is the clock the trigger starts.

In an IVF cycle, egg retrieval is scheduled 34 to 36 hours after the trigger, which means aspirating the follicles at the last point before they rupture. Go earlier and the eggs have not finished maturing, so a higher share come back immature and cannot be fertilised. Go later and the follicles have already released, the eggs are in the pelvis, and the retrieval collects nothing. This is why clinics give trigger times to the minute and why a 9:15 pm instruction is not a rounded 9:00 pm.

In an IUI or timed intercourse cycle the same clock applies with a different endpoint. Insemination is usually scheduled 24 to 36 hours after the trigger, timed to place sperm ahead of the egg rather than behind it.

There is a verification step worth knowing about. Some clinics draw a serum hCG level 8 to 12 hours after the injection to confirm the drug was actually absorbed. This is not bureaucratic. Failed or mistimed injections are the usual explanation for empty follicle syndrome, where follicles look right on ultrasound and yield no eggs, and a level drawn the morning after the trigger detects that problem while there is still time to act.

Dose equivalence across products

The numbers on the vials look wildly different, and most of that difference is unit systems rather than potency.

Preparation	Typical trigger dose	Route	Source
Urinary hCG	5,000 to 10,000 USP units	Intramuscular	Purified from the urine of pregnant women
Recombinant hCG	250 mcg, about 6,500 IU	Subcutaneous	Chinese hamster ovary cell culture
Low dose adjunct hCG	1,000 to 1,500 IU	Subcutaneous	Used alongside a GnRH agonist trigger in high risk cycles

The approved labelling for urinary hCG in ovulation induction is 5,000 to 10,000 USP units given one day after the last dose of menotropins, with 10,000 units the figure recommended in menotropin labelling. Recombinant hCG at 250 mcg was shown in registration studies to be clinically and statistically equivalent to urinary hCG at both 5,000 and 10,000 IU on oocyte yield and pregnancy outcome.

A 2003 review of the randomised data reached a conclusion that still holds and that is frequently ignored: a single 250 mcg dose of recombinant hCG was at least as effective as 5,000 or 10,000 IU of the urinary product, while a 500 mcg dose produced a higher rate of ovarian hyperstimulation syndrome with no improvement in pregnancy rates. More trigger is not more pregnancy. It is more risk.

The same review found midluteal progesterone ran higher after the recombinant product and injection site reactions were significantly less frequent, which is a purity effect rather than a potency one.

Urinary versus recombinant: what actually differs

Urinary hCG is extracted and purified from the urine of pregnant donors and standardised by biological assay. Recombinant hCG is manufactured in cell culture and standardised by mass, which is why it is dosed in micrograms. The physicochemical, immunological and biological activity of the recombinant hormone is described in the labelling as comparable to both placental and urine derived hCG, with the differences confined to the branching and sialylation of the attached sugar chains.

Practical differences that matter to a patient: the urinary product is intramuscular and comes as a powder requiring reconstitution with a supplied solvent, the recombinant product is subcutaneous and comes prefilled. The solvent supplied with the urinary product contains benzyl alcohol as a preservative, and once reconstituted the solution keeps for 60 days refrigerated. Anaphylaxis has been reported with urinary derived hCG products, which is uncommon but is on the label.

Cost runs the other way from convenience in most markets, which is the main reason urinary preparations remain in wide use worldwide.

When the trigger stops showing on a pregnancy test

This is the single most searched question about the trigger shot, and it gets answered with folklore more often than data.

The underlying pharmacology is straightforward. A home pregnancy test cannot distinguish hCG that came from a syringe from hCG made by a placenta. The injected dose has to fall below the test threshold before a positive result means anything. Standard home tests trigger somewhere between 10 and 25 mIU/mL, and early detection tests read lower, which extends the window rather than shortening it.

The clearance data that exists is older but specific. A Johns Hopkins study measured serum hCG after intramuscular injection in 34 women undergoing ovarian stimulation and found injected hCG remained detectable by immunoenzymetric assay for up to 14 days, with the decline following an exponential curve referenced to the level at 36 hours. A separate study dosing volunteers with repeated 5,000 unit injections and testing urine daily found a low threshold urine test, set at 50 units per litre, still positive in two of six women on day 11 and one of six on day 12, while a less sensitive test was negative in everyone.

Translating that into practical guidance:

Trigger dose	Usually undetectable on a home test by	Safe testing point
250 mcg recombinant, about 6,500 IU	Day 9 to 11	Day 12 or later
5,000 IU urinary	Day 9 to 11	Day 12 or later
10,000 IU urinary	Day 11 to 14	Day 14 or later

Count from the day of the injection, not from the day of the IUI or transfer. Body weight, kidney function, hydration and the sensitivity of the specific test all shift these edges, which is why the clinic beta test date is set where it is rather than where impatience would put it.

Testing out the trigger, and why clinics dislike it

Testing out means taking a home test daily from the day after the trigger, watching the line fade to negative, and then treating any subsequent darkening line as a real pregnancy. Done carefully it works, and for some people it converts a blank two week wait into something they can tolerate.

The failure modes are worth being clear-eyed about. A line that never fully disappears before implantation timing makes the reading ambiguous rather than reassuring. Evaporation lines and dye run patterns on cheap strips generate false hope routinely. And a faint positive at day 9 that fades by day 12 usually represents a very early loss, which is information most people would rather have received as a single negative beta at the scheduled date.

If you do it, use the same brand and the same test sensitivity throughout, use first morning urine, and treat the clinic beta as the only result that counts.

Ovarian hyperstimulation syndrome: the risk the trigger carries

hCG is the drug that converts a well stimulated cycle into a dangerous one. It binds LH receptors on enlarged ovaries and drives release of vasoactive substances that increase vascular permeability, allowing fluid to shift out of the circulation into the abdomen and occasionally the chest.

The timing pattern on the label is specific and useful: OHSS develops after gonadotropin treatment has stopped, can progress rapidly, and typically reaches its maximum about seven to ten days after treatment. It usually resolves on its own once menstruation starts. That last detail explains why an early pregnancy makes OHSS worse rather than better, since the placenta produces hCG that keeps the process running.

Early warning signs named on the label are severe pelvic pain, nausea, vomiting and weight gain. Abdominal distension, diarrhoea, marked ovarian enlargement, breathlessness and reduced urine output are all reported. Rapid weight gain after a trigger is the sign to act on, not to wait out.

Three risk reduction strategies exist and are worth understanding. Coasting, which means withholding gonadotropins for a day or more before triggering. Replacing the hCG trigger with a GnRH agonist trigger, which produces a shorter LH surge and a far lower OHSS rate, sometimes with a low dose of hCG added 35 hours later. And freezing all embryos so no pregnancy occurs in the cycle where the ovaries are already enlarged. If you have a high antral follicle count, PCOS, or a high estradiol reading before trigger, expect one of these to be proposed.

hCG for weight loss, and what the FDA requires on the label

hCG is sold widely, illegally in most cases, as a weight loss treatment. It does not work, and the regulatory position on this is unusually explicit.

Since 1975 the FDA has required every approved prescription hCG product to carry a statement in the indications section saying that hCG has not been shown to be effective additional therapy for obesity, that there is no substantial evidence it increases weight loss beyond what caloric restriction achieves, that it does not produce a better distribution of body fat, and that it does not reduce the hunger and discomfort of a calorie restricted diet. A meta-analysis of the available controlled and uncontrolled studies reached the same conclusion.

The weight loss seen on hCG diet protocols comes from the 500 calorie a day diet those protocols require, not from the hormone. Over the counter and homeopathic hCG products are not approved in any form, and oral and nasal formulations have no evidence of absorption at all. SafeRxPills stocks hCG as a fertility medicine. It is not a weight loss product and we will not describe it as one.

Handling, storage and injection technique

Urinary hCG arrives as a dried powder with a separate solvent vial. Sterile air is withdrawn from the powder vial and injected into the solvent vial, solvent is then transferred into the powder vial, and the vial is swirled gently until dissolved. Do not shake it. Inspect the solution for particles or discolouration before use and discard it if either is present.

Unopened vials are stored at controlled room temperature. Once reconstituted, refrigerate and use within 60 days. Each multiple dose vial is for a single patient only.

Urinary preparations are labelled for intramuscular use. Recombinant preparations are subcutaneous. Do not substitute the route because a shorter needle is easier; absorption profiles differ and the clinic timed your retrieval against a specific one.

Who should not receive hCG

The contraindications on the label are precocious puberty, prostatic carcinoma or another androgen dependent tumour, and a previous allergic reaction to hCG. Because hCG induces androgen secretion, which can cause fluid retention, the label advises caution in cardiac disease, kidney disease, epilepsy, migraine and asthma.

The label is also direct that hCG should be used alongside menopausal gonadotropins only by clinicians experienced in infertility who know the patient selection criteria and the warnings attached to menotropins. The serious adverse reactions named for this use are ovarian hyperstimulation, rupture of ovarian cysts with bleeding into the abdomen, multiple births, and arterial thromboembolism.

hCG and gonadotropin products stocked at SafeRxPills

Product	Strength	Price
IVFhCG 1500 IU	1,500 IU	$60.00
NeoHCG 5000	5,000 IU	$25.00
Fertigyn HP 5000	5,000 IU	$58.00
ZyhCG HP 5000	5,000 IU	$60.00
Lupi-HCG 5000	5,000 IU	$60.00
IVFhCG 5000iu	5,000 IU	$80.00
NeoHCG 10000	10,000 IU	$35.00
ZyhCG HP 10000	10,000 IU	$75.00
Sifasi HP 10000	10,000 IU	$75.00
Fertigyn HP 10000	10,000 IU	$79.00
Hucog 10000 HP	10,000 IU	$90.00
ZyhMG HP 75	Menotrophin 75 IU	$51.00
ZyHMG HP 150	Menotrophin 150 IU	$60.00
Menogo-Sure HP 150iu	Menotrophin 150 IU	$80.00

Menotrophin, also written hMG, is the stimulation drug that runs for days before the trigger, not the trigger itself. It contains both FSH and LH activity and grows the follicles that the hCG then matures and releases.

What to hold onto

The trigger is a timing instrument. Take it at the minute you were given, by the route on the prescription, and confirm with your clinic if anything about the injection went wrong, because an absorbed trigger and a missed one look identical from the outside until retrieval day.

A bigger dose is not a better trigger; 500 mcg of recombinant hCG bought more hyperstimulation and no more pregnancies than 250 mcg. And the positive test you take on day 8 is measuring the syringe, not the embryo. Count 12 days from a 5,000 IU dose and 14 from a 10,000 IU dose before a home test means anything at all.

What happens after the trigger matters just as much. See our guide to progesterone for luteal phase support for the part of the protocol that runs from the day after retrieval, and the overview on female infertility and ovulation induction for how the pieces fit together.

This article is for information only and is not a substitute for advice from a qualified prescriber. hCG is a prescription medicine and triggering is timed against a retrieval or insemination your clinic has scheduled. Never adjust the dose or the timing yourself, and contact your clinic immediately if you develop severe pelvic pain, vomiting, breathlessness or rapid weight gain after a trigger.

References

• DailyMed and FDA label, chorionic gonadotropin for injection USP: dosage for ovulation induction, reconstitution and storage, contraindications, ovarian hyperstimulation syndrome warnings and timing, cautions in cardiac, renal, epileptic, migraine and asthma patients
• DailyMed and FDA label, choriogonadotropin alfa prefilled syringe 250 mcg: composition, mechanism as an LH analogue, registration studies against urinary hCG at 5,000 and 10,000 IU, pharmacokinetics after subcutaneous administration
• PubMed PMID 12738494, Fertility and Sterility 2003: review of recombinant hCG in ovulation induction, dose equivalence against urinary hCG, the 500 mcg dose and ovarian hyperstimulation syndrome, midluteal progesterone and injection site tolerability
• Damewood and colleagues, Fertility and Sterility 1989, volume 52 page 398: disappearance of exogenously administered hCG measured in 34 women undergoing ovarian stimulation, detectable for up to 14 days after intramuscular injection
• PubMed PMID 3454503, Acta Europaea Fertilitatis 1987: interference of exogenous hCG with sensitive urine pregnancy tests after repeated 5,000 unit intramuscular doses, day by day positivity rates
• US Food and Drug Administration required labelling statement on hCG and obesity, in force since 1975, and the published meta-analysis of controlled and uncontrolled studies of hCG for weight loss